Author: Business Wire

Aerie Pharmaceuticals Receives Positive Feedback from FDA

IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary endpoint range of its second Phase 3 registration trial of

InSite Vision Announces Completion of the New Drug Application Submission to the U.S. FDA for BromSite

ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Incorporated (OTCBB:INSV) today announced that it has completed the submission to the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of BromSite™ for the treatment of inflammation and prevention of pain in cataract surgery. InSite is seeking marketing approval of BromSite in the United States. In its confirmatory Phase 3 clinical trials, BromSite achieved statistically significant superiority to vehicle in alleviating oc

LENSAR erhält CE-Kennzeichnung für fünf neue Leistungsanwendungsupgrades am LENSAR-Lasersystem

ORLANDO, Florida (USA)–(BUSINESS WIRE)–LENSAR Inc., ein globaler Führer in der Femtosekunden-Lasertechnologie für refraktive Kataraktchirurgie, hat heute mitgeteilt, dass es für eine Suite aus fünf neuen Anwendungstechnologien, die in das Vorzeigeprodukt des Unternehmens, das LENSAR® Laser System, integriert wurden, die CE-Kennzeichnung der Regulierungsbehörde der Europäischen Union erhalten hat. Als erste Femtosekunden-Laserkataraktplattform zur Ermöglichung der Automatisierung von Planungs-

LENSAR obtient le marquage CE pour cinq nouvelles mises à niveau d’application de performance du système laser LENSAR

ORLANDO, Floride–(BUSINESS WIRE)–LENSAR, Inc., un leader mondial en technologie laser femtoseconde de prochaine génération pour la chirurgie de la cataracte réfractive, a annoncé aujourd’hui que les régulateurs de l’Union européenne lui avaient accordé le marquage CE pour une série de cinq nouvelles technologies d’application intégrées au produit phare de la société, le système laser LENSAR®. En tant que première plateforme de cataracte laser femtoseconde à permettre l’automatisation des élém

Resumen: LENSAR recibe marcado CE para cinco nuevas actualizaciones de las prestaciones de las aplicaciones para el sistema láser LENSAR

ORLANDO, Fla.–(BUSINESS WIRE)–LENSAR, Inc., líder mundial en tecnología láser femtosegundo de próxima generación para la cirugía refractiva de cataratas, ha anunciado hoy que ha recibido el marcado CE de los organismos de la Unión Europea para una gama de cinco nuevas tecnologías de aplicaciones en el producto insignia de la compañía, el sistema láser LENSAR®. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ayuda y debe

Riassunto: LENSAR riceve il marchio CE per cinque nuovi aggiornamenti alle prestazioni dell’applicazione per il sistema laser LENSAR

ORLANDO, Florida–(BUSINESS WIRE)–LENSAR, Inc., leader a livello mondiale della tecnologia laser a femtosecondi di nuova generazione per la chirurgia refrattiva per cataratta, ha annunciato oggi di aver ricevuto il marchio CE da parte degli enti regolatori dell’Unione Europea per un pacchetto di cinque nuove tecnologie di applicazione integrate nel prodotto fiore all’occhiello della società, il sistema laser LENSAR®. Il testo originale del presente annuncio, redatto nella lingua di partenza, è

NovaBay Pharmaceuticals Conference Call Today, June 9th, 2015, at 12:00 p.m. Eastern Time

EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel approaches for the global eye care market including revolutionary non-antibiotic antimicrobial products, will host an investment community conference call today, June 9th, 2015. Management will discuss the attributes of its FDA-cleared intelli-Case for safely disinfecting contact lenses with hydrogen peroxide announced in its press release issued

InSite Vision to Merge With Canadian Biotechnology Company QLT

ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Inc. (OTCBB: INSV) today announced that it has reached a definitive agreement with QLT Inc. (NASDAQ: QLTI) (TSX: QLT) under which QLT will acquire InSite in an all-stock transaction that will create an ophthalmic specialty pharmaceutical company with a diversified portfolio of products, full R&D capabilities and innovative platform technologies. The transaction is expected to drive shareholder value by accelerating both companies’ development